June 2015
Volume 56, Issue 7
ARVO Annual Meeting Abstract  |   June 2015
Descemet stripping endothelial keratoplasty for Fuchs endothelial dystrophy: 5-year results of a prospective study.
Author Affiliations & Notes
  • Sanjay V Patel
    Ophthalmology, Mayo Clinic, Rochester, MN
  • Katrin Wacker
    Ophthalmology, Mayo Clinic, Rochester, MN
  • Jay W McLaren
    Ophthalmology, Mayo Clinic, Rochester, MN
  • Leo J Maguire
    Ophthalmology, Mayo Clinic, Rochester, MN
  • Keith H Baratz
    Ophthalmology, Mayo Clinic, Rochester, MN
  • Footnotes
    Commercial Relationships Sanjay Patel, None; Katrin Wacker, None; Jay McLaren, None; Leo Maguire, None; Keith Baratz, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 3977. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Sanjay V Patel, Katrin Wacker, Jay W McLaren, Leo J Maguire, Keith H Baratz; Descemet stripping endothelial keratoplasty for Fuchs endothelial dystrophy: 5-year results of a prospective study.. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):3977.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: To determine 5-year outcomes of Descemet stripping endothelial keratoplasty (DSEK) for Fuchs endothelial corneal dystrophy (FECD) in a prospective observational study.

Methods: Fifty eyes of 42 subjects with FECD (median age, 67 years: range 41- 87 years) were examined before DSEK and through 5 years after DSEK. All eyes were pseudophakic after surgery. Best-corrected visual acuity (BCVA) was measured by the electronic Early Treatment of Diabetic Retinopathy Study protocol, corneal power was measured by manual keratometry, anterior corneal haze was measured by confocal microscopy (ConfoScan 4), and central corneal thickness was measured by ultrasonic pachymetry (DGH 1000). Donor endothelial cell loss from preoperative was determined by digitizing apices (HAI CAS System) of endothelial cells in confocal images. Significances of changes after surgery were determined by using generalized estimating equation models to account for possible correlation between fellow eyes of the same subject. Data reported are for 31 eyes of 26 subjects who completed 5 years of follow-up.

Results: BCVA improved from 0.43 ± 0.21 logMAR (mean ± SD; Snellen equivalent, 20/54) before DSEK to 0.13 ± 0.16 logMAR (20/30) at 1 year (p<0.001), and further improved to 0.07 ± 0.13 logMAR (20/23) at 5 years (p=0.005 vs. 1 year). The proportion of eyes with BCVA better than 20/25 (Snellen equivalent) was 42% at 6 months, 52% at 1 year, and 65% at 5 years. Mean corneal power was 43.4 ± 1.3 D before DSEK and 43.3 ± 1.5 D at 5 years (p=0.33). Anterior corneal haze decreased from 2024 ± 605 scatter units (SU) before DSEK to 1901 ± 688 SU at 1 year (p<0.001), and continued to improve through 5 years (1492 ± 469 SU, p<0.001 vs. 1 year). Total corneal thickness did not change between 1 year (695 ± 54 µm) and 5 years (701 ± 57 µm, p=0.29). Endothelial cell loss at 5 years was 54 ± 15 %. Five grafts failed over the course of the study (included the surgeons’ earliest cases).

Conclusions: BCVA continues to improve between 1 and 5 years after DSEK. At 5 years, two-thirds of eyes see better than 20/25 despite a mean total corneal thickness of 700 µm. Improvement in vision is accompanied by continued reduction in corneal haze after 1 year, suggesting ongoing remodeling of the cornea after endothelial keratoplasty. The known hyperopic shift after DSEK is not explained by a change in power of the anterior corneal surface.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.